The continued emergence of new substances and changing patterns of drug use requires new health and harm reduction responses. New approaches in this field are needed to regularly update existing data on new drug trends and drug using patterns.
To collect information and observations from the perspective of harm reduction services will help in the development of new and effective interventions. Can current monitoring efforts, including the Early Warning System, be complemented with input from grassroots organisations?

Within the framework of C-EHRN, efforts have been made to monitor new drug trends by Correlation’s Focal Points. The idea behind is that CSO have easy access to PWUD and therefor to information about developments on the local drug markets such as emerging new substances, new routes of administration, new groups of users or new and unmet demands by drug user communities.

The aim of the session will be to discuss opportunities, the struggles and limitations to monitor new drug trends accurately and timely from a civil society perspective.

More specifically we would like to discuss the following topics:

• Which barriers and critical factors hinder the effective monitoring of new drug trends?
• Which success factors are at place in those countries, where monitoring is implemented effectively?
• How can countries and CSO overcome barriers and learn from other experiences?

Rafaela Rigoni (Correlation-European Harm Reduction Network)


  1. Daan van der Gouwe, Trimbos Institute – challenges and opportunities: what we learnt from the C EHRN monitoring of new drug trends (15 minutes)
  2. André Noor, EMCDDA – monitoring and data collection on new drug trends (15 minutes)

Local Experiences (10 min each)
       3. Ireland – Tony Duffin, Ana Liffey
       4. Switzerland – Dominique Schoori, Safer Party Zürich
       5. Spain – Mireia Ventura, Energy Control

Panel Discussion and Questions and Answers (30 min)

Would you like to join us?
Register via the link below!